trending Market Intelligence /marketintelligence/en/news-insights/trending/vBJ06cKGJlYh3r6cXubE5g2 content esgSubNav
In This List

Inspyr acquires Lewis & Clark Pharmaceuticals

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Inspyr acquires Lewis & Clark Pharmaceuticals

Inspyr Therapeutics Inc. on July 31 acquired privately held biotechnology company Lewis and Clark Pharmaceuticals Inc. in an all-stock transaction.

As consideration for the acquisition, the company agreed to issue an aggregate of 7,122,172 common shares to Lewis & Clark shareholders, resulting in the shareholders owning 50% of the issued and outstanding capital stock of Inspyr after the closing of the transaction.

In addition, Inspyr's board appointed John Montgomery, a principal of Lewis & Clark, to the board in connection with the deal. Montgomery's appointment, effective July 31, increases the size of the board to seven members from six members.